Yan Leyfman, MD
@yleyfman.bsky.social
Physician | Executive Director & Host MedNews Week | Medical Correspondent | Conference Director | Journal Editor | Educator | Research #Oncology #COVID19 #Immunotherapy #celltherapy #tcellrx #CART #bmtsm #MedSKY #ONCSKY | About Me: http://nyti.ms/2VG3gUK
Pinned
Yan Leyfman, MD
@yleyfman.bsky.social
· Nov 12
Park and Leyfman Hope to Advance Mission of MedNews Week Through Collaboration With OncLive
Chandler Park, MD, FACP, and Yan Leyfman, MD, discuss their partnership with OncLive and future goals for MedNews Week.
www.onclive.com
What sets MedNews Week apart? What are some exciting future initiatives?
Check out our latest feature for an exclusive behind-the-scenes look at the impact we're aiming to make with our unique partnership with Global Education Leader OncLive!
www.onclive.com/view/park-an...
Check out our latest feature for an exclusive behind-the-scenes look at the impact we're aiming to make with our unique partnership with Global Education Leader OncLive!
www.onclive.com/view/park-an...
Reposted by Yan Leyfman, MD
Brian Van Tine: The Truly Great Ones Leave Us Far Too Soon - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/voices/brian...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@yleyfman.bsky.social
oncodaily.com/voices/brian...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
Yan Leyfman: Brian Van Tine - The Truly Great Ones Leave Us Far Too Soon - OncoDaily
Yan Leyfman: Brian Van Tine - The Truly Great Ones Leave Us Far Too Soon / Brian Van Tine, cancer, OncoDaily, Oncology, Yan Leyfman
oncodaily.com
November 11, 2025 at 12:21 AM
Brian Van Tine: The Truly Great Ones Leave Us Far Too Soon - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/voices/brian...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
@yleyfman.bsky.social
oncodaily.com/voices/brian...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews
In life, we meet many people—many leaders, mentors, and friends—but the truly great ones leave us far too soon.
I met Dr. Brian Van Tine about four years ago at ASCO, and he immediately stood out as one of the most jovial, energetic, and compassionate individuals one could hope to meet.
I met Dr. Brian Van Tine about four years ago at ASCO, and he immediately stood out as one of the most jovial, energetic, and compassionate individuals one could hope to meet.
November 10, 2025 at 3:23 AM
In life, we meet many people—many leaders, mentors, and friends—but the truly great ones leave us far too soon.
I met Dr. Brian Van Tine about four years ago at ASCO, and he immediately stood out as one of the most jovial, energetic, and compassionate individuals one could hope to meet.
I met Dr. Brian Van Tine about four years ago at ASCO, and he immediately stood out as one of the most jovial, energetic, and compassionate individuals one could hope to meet.
An important perspective on medical misinformation in the modern era.
www.medscape.com/viewarticle/...
www.medscape.com/viewarticle/...
Cancer Misinformation: When Influencers Co-Opt Care
Experts explore the messy intersection between evidence-based cancer care and an enticing wellness industry dominated by social media influencers who often spread cancer misinformation.
www.medscape.com
November 8, 2025 at 4:25 PM
An important perspective on medical misinformation in the modern era.
www.medscape.com/viewarticle/...
www.medscape.com/viewarticle/...
Thank you to OncLive for the opportunity to share my thoughts on this important update.
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
Clinical Implications Remain After Dasatinib CRL in CML/ALL | CancerNetwork
The FDA's CRL for the HyNap formulation of dasatinib due to manufacturing issues does not affect the efficacy or availability of standard dasatinib.
www.cancernetwork.com
October 30, 2025 at 5:33 AM
Thank you to OncLive for the opportunity to share my thoughts on this important update.
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
www.cancernetwork.com/view/clinica...
@onclive.bsky.social
Reposted by Yan Leyfman, MD
Honored to Join the Advisory Board of CancerNetwork - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/career/advis...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork
@yleyfman.bsky.social
oncodaily.com/career/advis...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork
Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork - OncoDaily
Yan Leyfman: Honored to Join the Advisory Board of CancerNetwork / cancer, CancerNetwork, OncoDaily, Oncology, ONCOLOGY/CancerNetwork, Yan Leyfman
oncodaily.com
September 24, 2025 at 3:02 PM
Honored to Join the Advisory Board of CancerNetwork - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/career/advis...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork
@yleyfman.bsky.social
oncodaily.com/career/advis...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerNetwork
I’m deeply honored to join the Advisory Board of ONCOLOGY / CancerNetwork. 🎉 Thank you to Ariana Pelosci & the editorial team for this invitation — I’m grateful for the opportunity to work alongside such an esteemed group of clinical and scientific leaders. 🙏
September 23, 2025 at 10:53 PM
I’m deeply honored to join the Advisory Board of ONCOLOGY / CancerNetwork. 🎉 Thank you to Ariana Pelosci & the editorial team for this invitation — I’m grateful for the opportunity to work alongside such an esteemed group of clinical and scientific leaders. 🙏
Grateful to the Humanity Rx Podcast for highlighting my story, my passion for oncology & my commitment to advancing patient care & research innovation.
As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.
As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.
pod.link
September 3, 2025 at 4:25 AM
Grateful to the Humanity Rx Podcast for highlighting my story, my passion for oncology & my commitment to advancing patient care & research innovation.
As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.
As one of the few remaining survivors of the after-effects of Chernobyl, my own complex medical journey as a child shaped my path toward medicine.
Reposted by Yan Leyfman, MD
Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - OncoDaily
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL / Bristol Myers Squibb, cancer, FDA,
oncodaily.com
August 10, 2025 at 7:09 PM
Yan Leyfman: FDA Accepts Bristol Myers Squibb’s Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
@yleyfman.bsky.social @bristolmyerssquibb.bsky.social
oncodaily.com/voices/yan-l...
#Cancer #Oncology #OncoDaily #Health #Medicine
🎥 MedNews Week x OncLive x Women in Lymphoma Present:
🌟 Voices in Lymphoma: Women Shaping Care 🌟
Career Development & Mentorship in Medicine
🗓️ Tuesday, August 12
⏰ 6:30 PM EST
🌟 Voices in Lymphoma: Women Shaping Care 🌟
Career Development & Mentorship in Medicine
🗓️ Tuesday, August 12
⏰ 6:30 PM EST
August 6, 2025 at 4:31 AM
🎥 MedNews Week x OncLive x Women in Lymphoma Present:
🌟 Voices in Lymphoma: Women Shaping Care 🌟
Career Development & Mentorship in Medicine
🗓️ Tuesday, August 12
⏰ 6:30 PM EST
🌟 Voices in Lymphoma: Women Shaping Care 🌟
Career Development & Mentorship in Medicine
🗓️ Tuesday, August 12
⏰ 6:30 PM EST
🧪 Real-world study supports talquetamab as a viable bridging strategy to BCMA CAR-T in RRMM 🔄
📌 Key Takeaways:
Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.
📌 Key Takeaways:
Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.
Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy
Key Points. Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity.Talquetamab enabled transition
ashpublications.org
August 2, 2025 at 11:00 PM
🧪 Real-world study supports talquetamab as a viable bridging strategy to BCMA CAR-T in RRMM 🔄
📌 Key Takeaways:
Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.
📌 Key Takeaways:
Talquetamab bridging is feasible, safe, and effective, enabling rapid disease control with low-grade toxicities.
🧬✨ Hope Through Mitochondrial Donation
A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.
A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.
Mitochondrial Donation in a Reproductive Care Pathway for mtDNA Disease | NEJM
Pathogenic variants in mitochondrial DNA (mtDNA) are a common cause of severe, often
fatal, inherited metabolic disease. A reproductive care pathway was implemented to
provide women carrying pathog...
www.nejm.org
July 27, 2025 at 3:36 PM
🧬✨ Hope Through Mitochondrial Donation
A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.
A UK reproductive program offering pronuclear transfer (a form of mitochondrial donation) to women with pathogenic mtDNA variants has resulted in 8 healthy live births.
🎥 MedNews Week x OncLive x Women in Lymphoma Present:
🌟 Voices in Lymphoma: Women Shaping Care 🌟
💡 Follicular Lymphoma: General Concept and First Line Strategies
🗓️ Tuesday, July 15
⏰ 6:30 PM EST
🌟 Voices in Lymphoma: Women Shaping Care 🌟
💡 Follicular Lymphoma: General Concept and First Line Strategies
🗓️ Tuesday, July 15
⏰ 6:30 PM EST
July 8, 2025 at 1:57 AM
🎥 MedNews Week x OncLive x Women in Lymphoma Present:
🌟 Voices in Lymphoma: Women Shaping Care 🌟
💡 Follicular Lymphoma: General Concept and First Line Strategies
🗓️ Tuesday, July 15
⏰ 6:30 PM EST
🌟 Voices in Lymphoma: Women Shaping Care 🌟
💡 Follicular Lymphoma: General Concept and First Line Strategies
🗓️ Tuesday, July 15
⏰ 6:30 PM EST
Reposted by Yan Leyfman, MD
AI’s Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #NPC #NasopharyngealCarcinoma
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #NPC #NasopharyngealCarcinoma
Yan Leyfman: AI's Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - OncoDaily
Yan Leyfman: AI's Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma / C. Huang, C. Xie, cancer, Cancer research, F. Xie, F. Zhong, J. Chen,
oncodaily.com
July 5, 2025 at 11:08 PM
AI’s Role in Guiding Immunotherapy Decisions in Nasopharyngeal Carcinoma - Yan Leyfman
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #NPC #NasopharyngealCarcinoma
@yleyfman.bsky.social
oncodaily.com/insight/yan-...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #AI #NPC #NasopharyngealCarcinoma
A breakthrough for blood cancer detection?
In a Nature Medicine study—published just days after their labs were damaged in an Iranian missile attack—Shlush, Tanay, Furer, Milman & Rappoport reveal a potential game-changer:
In a Nature Medicine study—published just days after their labs were damaged in an Iranian missile attack—Shlush, Tanay, Furer, Milman & Rappoport reveal a potential game-changer:
A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics - Nature Medicine
A large single-cell transcriptomic-based reference model for hematopoietic stem and progenitor cells from 148 age- and sex-diverse individuals identifies physiological and disease-specific changes acr...
www.nature.com
June 27, 2025 at 10:20 PM
A breakthrough for blood cancer detection?
In a Nature Medicine study—published just days after their labs were damaged in an Iranian missile attack—Shlush, Tanay, Furer, Milman & Rappoport reveal a potential game-changer:
In a Nature Medicine study—published just days after their labs were damaged in an Iranian missile attack—Shlush, Tanay, Furer, Milman & Rappoport reveal a potential game-changer:
🚨 Latest in Type 2 Diabetes & Weight Management 🚨
New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.
New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes | NEJM
Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor
agonist in clinical development for type 2 diabetes and weight management. Additional
data on the efficacy and ...
www.nejm.org
June 23, 2025 at 11:47 PM
🚨 Latest in Type 2 Diabetes & Weight Management 🚨
New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.
New data from the phase 3 ACHIEVE-1 trial shows promising results for Orforglipron, a once-daily, oral, nonpeptide GLP-1 receptor agonist.
🚨 Historic FDA Approval Alert! 🚨
The FDA has just approved Yeztugo (lenacapavir) — a game-changing HIV prevention drug that offers **near-complete protection with just 1 injection every 6 months. 💉🛡️
www.statnews.com/2025/06/18/f...
The FDA has just approved Yeztugo (lenacapavir) — a game-changing HIV prevention drug that offers **near-complete protection with just 1 injection every 6 months. 💉🛡️
www.statnews.com/2025/06/18/f...
HIV protection with just two shots a year: FDA approves Gilead drug
A new twice-yearly shot could be a "game changer" in the fight against AIDS, but experts' hopes have dimmed because of the current political climate.
www.statnews.com
June 18, 2025 at 6:44 PM
🚨 Historic FDA Approval Alert! 🚨
The FDA has just approved Yeztugo (lenacapavir) — a game-changing HIV prevention drug that offers **near-complete protection with just 1 injection every 6 months. 💉🛡️
www.statnews.com/2025/06/18/f...
The FDA has just approved Yeztugo (lenacapavir) — a game-changing HIV prevention drug that offers **near-complete protection with just 1 injection every 6 months. 💉🛡️
www.statnews.com/2025/06/18/f...
🔬 AI Meets Hematopathology 🧬
Bone marrow slide interpretation is complex, time-consuming, and prone to error. A new deep learning model, DeepHeme, changes the game.
Bone marrow slide interpretation is complex, time-consuming, and prone to error. A new deep learning model, DeepHeme, changes the game.
June 17, 2025 at 2:42 PM
🔬 AI Meets Hematopathology 🧬
Bone marrow slide interpretation is complex, time-consuming, and prone to error. A new deep learning model, DeepHeme, changes the game.
Bone marrow slide interpretation is complex, time-consuming, and prone to error. A new deep learning model, DeepHeme, changes the game.
Great presentation about the efficacy of Bispecific Chimeric T Cell Receptors for cancer therapy at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Stanley Riddell of FRED HUTCHINSON CANCER RESEARCH
June 16, 2025 at 9:06 PM
Great presentation about the efficacy of Bispecific Chimeric T Cell Receptors for cancer therapy at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Stanley Riddell of FRED HUTCHINSON CANCER RESEARCH
Great presentation about the promise of armored CAR T cells without lymphodepletion therapy at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Renier Brentjens of Roswell Park Comprehensive Cancer Center.
June 16, 2025 at 8:44 PM
Great presentation about the promise of armored CAR T cells without lymphodepletion therapy at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Renier Brentjens of Roswell Park Comprehensive Cancer Center.
🚨 New Study Alert: CAR-T Prep Reimagined!
Can bendamustine replace Flu/Cy as lymphodepleting chemo before CAR-T in relapsed/refractory #NHL?
🧪 In a large real-world study (n=265), bendamustine showed:
Can bendamustine replace Flu/Cy as lymphodepleting chemo before CAR-T in relapsed/refractory #NHL?
🧪 In a large real-world study (n=265), bendamustine showed:
June 16, 2025 at 6:45 PM
🚨 New Study Alert: CAR-T Prep Reimagined!
Can bendamustine replace Flu/Cy as lymphodepleting chemo before CAR-T in relapsed/refractory #NHL?
🧪 In a large real-world study (n=265), bendamustine showed:
Can bendamustine replace Flu/Cy as lymphodepleting chemo before CAR-T in relapsed/refractory #NHL?
🧪 In a large real-world study (n=265), bendamustine showed:
Great Gene Editing Keynote highlighting the promise & potential of CAR-M at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Saar Gill of University of Pennsylvania.
June 16, 2025 at 4:59 PM
Great Gene Editing Keynote highlighting the promise & potential of CAR-M at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Global Immunotherapy Leader Dr. Saar Gill of University of Pennsylvania.
Great Keynote address highlighting the history of PD-1/PD-L1 inhibitors at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Dr. Antoni Ribas of UCLA.
#nyas #cancerimmunotherapy #io #cancerimmunotherapy25 #cancerimmunotherapy2025
#nyas #cancerimmunotherapy #io #cancerimmunotherapy25 #cancerimmunotherapy2025
June 16, 2025 at 2:32 PM
Great Keynote address highlighting the history of PD-1/PD-L1 inhibitors at the 2025 The New York Academy of Sciences Frontiers in Cancer Immunotherapy Symposium by Dr. Antoni Ribas of UCLA.
#nyas #cancerimmunotherapy #io #cancerimmunotherapy25 #cancerimmunotherapy2025
#nyas #cancerimmunotherapy #io #cancerimmunotherapy25 #cancerimmunotherapy2025
Reposted by Yan Leyfman, MD
Tomorrow @ 6:30pm EST
MedNewsWeek x OncLive x WiL Present:
Voices in Lymphoma: Women Shaping Care
A powerful conversation on evolving paradigms in first relapse DLBCL with two trailblazing experts Dr Manali Kamdar & Dr Sonali Smith
bsky.app/profile/yley...
MedNewsWeek x OncLive x WiL Present:
Voices in Lymphoma: Women Shaping Care
A powerful conversation on evolving paradigms in first relapse DLBCL with two trailblazing experts Dr Manali Kamdar & Dr Sonali Smith
bsky.app/profile/yley...
🎥 MedNews Week x OncLive x Women in Lymphoma Present:
🌟 Voices in Lymphoma: Women Shaping Care 🌟
🔥 New Episode – June 17! 🔥
Dive into a must-watch conversation on evolving paradigms in first relapse DLBCL with two powerhouse leaders in lymphoma care:
👩⚕️ Dr. Sonali Smith
👩⚕️ Dr. Manali Kamdar
🌟 Voices in Lymphoma: Women Shaping Care 🌟
🔥 New Episode – June 17! 🔥
Dive into a must-watch conversation on evolving paradigms in first relapse DLBCL with two powerhouse leaders in lymphoma care:
👩⚕️ Dr. Sonali Smith
👩⚕️ Dr. Manali Kamdar
June 16, 2025 at 8:22 AM
Tomorrow @ 6:30pm EST
MedNewsWeek x OncLive x WiL Present:
Voices in Lymphoma: Women Shaping Care
A powerful conversation on evolving paradigms in first relapse DLBCL with two trailblazing experts Dr Manali Kamdar & Dr Sonali Smith
bsky.app/profile/yley...
MedNewsWeek x OncLive x WiL Present:
Voices in Lymphoma: Women Shaping Care
A powerful conversation on evolving paradigms in first relapse DLBCL with two trailblazing experts Dr Manali Kamdar & Dr Sonali Smith
bsky.app/profile/yley...
🚨 MedNews Week KEYNOTE Conference 🚨
We’re honored to welcome Dr. Markus Mapara, world-renowned leader in transplantation and cell therapy, as our next MedNews Week x OncLive Keynote Speaker! 🧬
🎥 : www.onclive.com/view/allogen...
We’re honored to welcome Dr. Markus Mapara, world-renowned leader in transplantation and cell therapy, as our next MedNews Week x OncLive Keynote Speaker! 🧬
🎥 : www.onclive.com/view/allogen...
June 13, 2025 at 9:29 PM
🚨 MedNews Week KEYNOTE Conference 🚨
We’re honored to welcome Dr. Markus Mapara, world-renowned leader in transplantation and cell therapy, as our next MedNews Week x OncLive Keynote Speaker! 🧬
🎥 : www.onclive.com/view/allogen...
We’re honored to welcome Dr. Markus Mapara, world-renowned leader in transplantation and cell therapy, as our next MedNews Week x OncLive Keynote Speaker! 🧬
🎥 : www.onclive.com/view/allogen...
🧬 Breakthrough in Organoid Vascularization!
A major step forward in modeling human development 🔬
Stanford reseachers have successfully created vascularized cardiac and hepatic organoids from human pluripotent stem cells, mimicking early human organ development with remarkable fidelity.
A major step forward in modeling human development 🔬
Stanford reseachers have successfully created vascularized cardiac and hepatic organoids from human pluripotent stem cells, mimicking early human organ development with remarkable fidelity.
Gastruloids enable modeling of the earliest stages of human cardiac and hepatic vascularization
Although model organisms have provided insight into the earliest stages of cardiac and hepatic vascularization, we know very little about this process in humans because of ethical restrictions and the...
www.science.org
June 11, 2025 at 9:02 PM
🧬 Breakthrough in Organoid Vascularization!
A major step forward in modeling human development 🔬
Stanford reseachers have successfully created vascularized cardiac and hepatic organoids from human pluripotent stem cells, mimicking early human organ development with remarkable fidelity.
A major step forward in modeling human development 🔬
Stanford reseachers have successfully created vascularized cardiac and hepatic organoids from human pluripotent stem cells, mimicking early human organ development with remarkable fidelity.